16/09/2025 Selexipag for treating pulmonary arterial hypertension
The Ministry of Health’s Drug Advisory Committee has recommended:
- Selexipag 200 mcg, 400 mcg, 600 mcg and 800 mcg tablet, to be added as the second or third drug in a combination treatment for pulmonary arterial hypertension, in line with the following criteria:
- Patient is already receiving an endothelin receptor antagonist and/or a phosphodiesterase type 5 inhibitor at maximum tolerated doses; and
- Prior to adding selexipag treatment, patient is assessed to have intermediate to high risk of 1-year mortality (according to the European Society of Cardiology/European Respiratory Society risk-stratification tool) during follow-up.
Funding status
RSelexipag 200 mcg, 400 mcg, 600 mcg and 800 mcg tablets are recommended for inclusion on the Medication Assistance Fund (MAF) for the abovementioned indication from 1 November 2025.
NRHigher-strength tablets of selexipag (1,000 mcg, 1,200 mcg, 1,400 mcg and 1,600 mcg) have not been recommended for inclusion on the MAF as they are currently not marketed in Singapore.